Myasthenia gravis (MG) is a chronic autoimmune disease characterized by fluctuating muscle weakness, which, in the majority of patients, is treated with corticosteroids. In a recently published clinical trial, 50 patients with generalized MG were randomly assigned to prednisone + methotrexate or prednisone + placebo. The amount of prednisone that the patients used over 12 months did not differ between the methotrexate and placebo groups, indicating that this drug does not have a steroid-sparing effect in patients with MG.